Home Drug IndexClinical Monograph

Tiotropium Uses, Dosage, Side Effects & Price | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Bronchodilator

Subclass

Long-acting muscarinic antagonist (LAMA)

Speciality

Pulmonology

Schedule (India)

schedule H

Routes

Inhalation

Formulations

Inhalation powder in hard capsules: 18 mcg per capsule (for use with HandiHaler® or equivalent device)
Metered dose inhaler (MDI): 2.5 mcg per actuation
Respimat® soft-mist inhaler: 2.5 mcg per puff

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Chronic Obstructive Pulmonary Disease (COPD) — Maintenance Bronchodilator

Parameter	Dry Powder Capsule (HandiHaler)	Soft-Mist Inhaler (Respimat)
Starting dose	18 mcg once daily	5 mcg (2 puffs) once daily
Titration	Not applicable	Not applicable
Usual maintenance dose	18 mcg once daily	5 mcg (2 puffs) once daily
Maximum dose	18 mcg/day	5 mcg/day

Clinical Notes:

NOT indicated for acute bronchospasm or rescue therapy
Administer at the same time each day
For HandiHaler: capsule must be punctured and drug inhaled with forceful deep inspiration
Respimat preferred for patients with poor inspiratory flow or dexterity issues

2. Asthma — Maintenance Controller (Add-on therapy when ICS + LABA insufficient)

Parameter	Respimat Only
Starting dose	5 mcg (2 puffs) once daily
Titration	Not applicable
Usual maintenance dose	5 mcg (2 puffs) once daily
Maximum dose	5 mcg/day

Clinical Notes:

Reserved for moderate-to-severe asthma uncontrolled on ICS + LABA
Requires pulmonologist supervision
Dry powder form NOT approved for asthma in India
Continue ICS and LABA alongside; do not use as monotherapy

Secondary Indications — Adults (Off-label, if any)

Indication	Dose	Duration	Supervision	Label Status	Evidence Basis
Bronchiectasis (non-CF) with airflow obstruction	18 mcg once daily via HandiHaler	Long-term if benefit documented	Specialist only	OFF-LABEL	Small RCTs; Indian pulmonology practice

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications

Age Restriction: Tiotropium Respimat is approved for children ≥6 years for asthma in some countries. INDIAN PAEDIATRIC INDICATION NOT EXPLICITLY APPROVED BY CDSCO OR IAP.

Asthma — Add-on Maintenance Therapy (Specialist Use Only)

Age Group	Starting Dose	Titration	Usual Maintenance	Maximum Dose	Notes
≥6 to <12 years	2.5 mcg (1 puff) once daily via Respimat	May increase after 4–6 weeks if inadequate response	2.5–5 mcg once daily	5 mcg/day	OFF-LABEL in India
≥12 years	5 mcg (2 puffs) once daily via Respimat	Not applicable	5 mcg once daily	5 mcg/day	OFF-LABEL in India

Safety Monitoring:

Monitor FEV1 response at 4–6 weeks
Ensure adherence to ICS therapy
Assess inhaler technique regularly

Children <6 years: NOT RECOMMENDED except in clinical trial settings

Secondary Indications — Paediatric Doses (Off-label, if any)

Not applicable.

Renal Adjustments

eGFR (mL/min/1.73 m²)	Recommendation
≥30 (Mild–Moderate impairment)	No dose adjustment required
<30 (Severe impairment)	Use with caution; monitor for anticholinergic adverse effects (dry mouth, urinary retention, constipation) due to reduced renal clearance
Haemodialysis	No specific data; use with caution

Hepatic adjustment

Contraindications

Known hypersensitivity to tiotropium, atropine, or atropine derivatives (e.g., ipratropium)
Hypersensitivity to inhaled lactose (for dry powder capsule formulation)
Use as rescue therapy for acute bronchospasm

Cautions

Narrow-angle glaucoma: May precipitate or worsen acute angle-closure if mist/powder contacts eyes
Urinary retention: Use cautiously in men with prostatic hyperplasia or bladder neck obstruction
Moderate-to-severe renal impairment: Increased risk of systemic anticholinergic effects
Inhalation technique: Suboptimal technique significantly reduces drug delivery and efficacy
Do NOT nebulise: Product not designed for nebuliser use
Paradoxical bronchospasm: Discontinue immediately if occurs
Cardiovascular disease: Use cautiously in patients with recent myocardial infarction or unstable arrhythmia

Pregnancy

Parameter	Recommendation
Risk category/Safety statement	Limited human data; animal studies suggest low risk
Preferred alternatives	Inhaled corticosteroids (ICS) and LABAs (e.g., budesonide, formoterol) are better studied in pregnancy
When it may be used	When benefit clearly outweighs risk in moderate-to-severe COPD/asthma uncontrolled on other agents
Monitoring	Pulmonary function; fetal growth on ultrasound if prolonged use

Lactation

Parameter	Recommendation
Compatibility	Likely compatible due to minimal systemic absorption via inhalation
Preferred alternatives	Continue if clinically necessary for disease control
Expected drug levels in milk	Negligible (low systemic absorption)
Infant monitoring	Observe for signs of anticholinergic exposure: poor feeding, dry mouth, irritability (unlikely)

Elderly

Parameter	Recommendation
Starting dose	Same as younger adults (no age-based dose adjustment)
Titration	Not required; slower titration unnecessary unless comorbidities present
Extra risks	Dry mouth, urinary retention, constipation, confusion — especially with severe renal impairment or anticholinergic polypharmacy
Device preference	Respimat may be preferred over DPI in those with poor inspiratory effort

Major drug interactions

Interacting Drug(s)	Effect/Mechanism	Recommendation
Other inhaled antimuscarinics (e.g., ipratropium, glycopyrronium, umeclidinium)	Additive anticholinergic effects — increased risk of dry mouth, urinary retention, constipation, confusion	Avoid concurrent use
Systemic anticholinergics (e.g., oxybutynin, tolterodine)	Additive anticholinergic burden	Avoid or use with extreme caution

Moderate drug interactions

Interacting Drug(s)	Effect/Mechanism	Recommendation
Inhaled beta-agonists (salbutamol, formoterol, salmeterol)	Often co-administered; additive cardiovascular effects (tachycardia, tremor) possible	Monitor; generally safe combination
Inhaled corticosteroids (ICS)	Commonly used together for asthma/COPD	Safe combination; no dose adjustment
Potassium-lowering agents (loop/thiazide diuretics)	Hypokalaemia may increase arrhythmia risk when combined with beta-agonists	Monitor potassium if triple therapy
Tricyclic antidepressants, sedating antihistamines	Increased total anticholinergic burden	Monitor for adverse effects

Note: Tiotropium is primarily renally excreted with no significant CYP450 interactions.

Common Adverse effects

Dry mouth (xerostomia) — most frequent
Constipation
Cough post-inhalation
Pharyngitis / throat irritation
Headache
Sinusitis

Serious Adverse effects

Adverse Effect	Clinical Significance
Paradoxical bronchospasm	Discontinue immediately; treat as acute bronchospasm
Acute angle-closure glaucoma	Can occur if mist/powder contacts eye; urgent ophthalmology referral
Urinary retention	Particularly in elderly men with prostatic hypertrophy; may require catheterisation
Hypersensitivity reactions	Rash, urticaria, angioedema, anaphylaxis — discontinue permanently
Supraventricular tachycardia / atrial fibrillation	Rare; monitor in patients with pre-existing cardiac disease

Monitoring requirements

Timing	Parameter
Baseline	Spirometry (FEV1, FVC); symptom burden assessment (mMRC, CAT score for COPD)
After initiation (4–6 weeks)	Assess bronchodilator response; review inhaler technique; evaluate symptom improvement
Long-term	Monitor for dry mouth, urinary symptoms; intraocular pressure in glaucoma-prone patients; renal function if impaired at baseline
Renal impairment	Monitor for systemic anticholinergic side effects

Brands in India

Spiriva®	Boehringer Ingelheim	Dry powder capsule; Respimat
Tiova®	Cipla	Dry powder capsule
Tiova Respimat®	Cipla	Soft-mist inhaler
T Spiriva®	Sun Pharma	Dry powder capsule
Tiomate®	Cipla	FDC with LABA (DPI) — note: fixed-dose combination

Price range (INR)

Formulation	Approximate Price
DPI capsule (18 mcg)	₹15–30 per capsule
Respimat cartridge (4 weeks supply)	₹1,000–1,600

Note: May be available at subsidised rates in government settings under NLEM provisions for COPD.

Clinical pearls

Device selection matters: Prefer Respimat for elderly patients or those with poor inspiratory flow; DPI requires forceful inhalation for adequate drug deposition.
Technique is critical: Always verify inhaler technique at every visit — incorrect use is a common cause of treatment failure.
Not for rescue: Tiotropium is strictly preventive/maintenance therapy; never prescribe for acute symptom relief.
Eye protection: Advise patients to avoid spraying toward eyes, especially with Respimat — can precipitate acute glaucoma.
Asthma positioning: In asthma, tiotropium is a Step 4/5 add-on only when ICS + LABA are insufficient; never use as monotherapy.
Anticholinergic burden: Screen for concomitant anticholinergic medications in elderly to prevent cumulative toxicity.

Version

RxIndia v1.0 — 19 Jun 2025

Reference

- CDSCO (Form 45 and product inserts)
- Indian Pharmacopoeia / National Formulary of India (IP/NFI) 2021
- National List of Essential Medicines (NLEM) 2022
- API Textbook of Medicine
- ICMR COPD Management Guidelines
- Indian Chest Society Expert Guidelines
- AIIMS Formulary and Clinical Protocols
- Select RCTs/meta-analyses (for off-label bronchiectasis and paediatric asthma use)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...